Phase 3 Clinical Trials With Primary Completion Dates in March 2018
This is a list of Phase 3 trials with primary completion dates in March 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ADMS | Adamas Pharmaceuticals, Inc. | 2018-03-01 | Phase 3 | NCT02202551 | Open-Label Safety Study of ADS-5102 in PD Patients With LID |
| AXON | Axovant Sciences Ltd. | 2018-03-01 | Phase 3 | NCT02586909 | 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension |
| DERM | Dermira, Inc. | 2018-03-01 | Phase 3 | NCT03073486 | A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris |
| DERM | Dermira, Inc. | 2018-03-01 | Phase 3 | NCT03028363 | A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris |
| EARS | Auris Medical Holding AG | 2018-03-01 | Phase 3 | NCT02809118 | Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment |
| FGEN | FibroGen, Inc | 2018-03-01 | Phase 3 | NCT02273726 | Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects |
| FGEN | FibroGen, Inc | 2018-03-01 | Phase 3 | NCT02052310 | Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients |
| FGEN | FibroGen, Inc | 2018-03-01 | Phase 3 | NCT01750190 | A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis |
| FGEN | FibroGen, Inc | 2018-03-01 | Phase 3 | NCT02021318 | Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa |
| GRFS | Grifols, S.A. | 2018-03-01 | Phase 3 | NCT02413580 | A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations |
| OBSV | ObsEva SA | 2018-03-01 | Phase 3 | NCT03081208 | Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI |
| PTCT | PTC Therapeutics, Inc. | 2018-03-01 | Phase 3 | NCT01557400 | Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada |
| SHPG | Shire plc | 2018-03-01 | Phase 3 | NCT03004924 | Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo |
| SHPG | Shire plc | 2018-03-01 | Phase 3 | NCT02340819 | Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS) |
| SUPN | Supernus Pharmaceuticals, Inc. | 2018-03-01 | Phase 3 | NCT02618408 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1) |
| TBPH | Theravance Biopharma, Inc. | 2018-03-01 | Phase 3 | NCT02208063 | A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial |
| VRX | Valeant Pharmaceuticals International, Inc. | 2018-03-01 | Phase 3 | NCT03058783 | Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects |